Breaking Records: RDE Inc. Sees 130% Growth in Second Quarter, Generating $1.8 Million in Revenue and $0.01 EPS for First Half of 2022

Business-to-Business Partnerships Accelerating Revenue Growth and Profitability ATLANTA, GA, Aug. 03, 2022 (GLOBE NEWSWIRE) — RDE, Inc. (OTCQB: RSTN) (the “Company”), the owner and operator of Restaurant.com, the nation’s largest restaurant-focused digital deals brand, today announced financial and operational results for the second quarter ended June 30, 2022. Key Financial Highlights for: Three Months Ended…

Read More

Get the Scoop: Independent Proxy Advisory Firms ISS and Glass Lewis Urge Catalyst Stockholders to Vote for All of the Company’s Nominees on the White Proxy Card!

ISS and Glass Lewis Recommend Stockholders Vote “FOR” All of Catalyst’s Nominees The Incumbent Board’s Cash Distribution Plan Supported by Leading Proxy Advisory Firms Recently, leading independent proxy advisory firms ISS and Glass Lewis have recommended that stockholders of Catalyst Biosciences, Inc. vote “FOR” all of the company’s nominees. This decision comes after careful consideration…

Read More

Real-Time Technologies Acquires InComm Agent Solutions: A Game-Changing Addition to Our Retail Footprint!

Welcome to the Future of Retail Management Software Real Time Technologies Acquires InComm Agent Solutions August 3, 2022 Exciting news in the technology world as Real Time Technologies, Inc (RT²) has announced its acquisition of InComm Agent Solutions. This strategic move not only adds critical payments technology to RT²’s core business, but also expands serviceable…

Read More

Spain’s July Services PMI Surprises at 53.8, Beating Expectations of 52.0 – A Positive Sign for the Economy!

Spain’s July Services PMI Surprises at 53.8, Beating Expectations of 52.0 – A Positive Sign for the Economy! Description: Prior 54.0Spain’s services sector continues to hold up in July, signaling another expansion with a modest rise in new business. But there are growing concerns about the outlook amid high inflation and economic uncertainty as business…

Read More

Breaking News: FDA Gives Green Light to Coherus’ Cimerli (Ranibizumab EQRN) as the First Interchangeable Biosimilar to Lucentis for All 5 Indications with 12 Months of Interchangeability Exclusivity!

FDA Approves Coherus’ CIMERLI™ Introducing Coherus’ Latest FDA Approved Product Coherus Biosciences, a leading biotechnology company, has received FDA approval for their newest product, CIMERLI™. This marks Coherus’ third FDA-approved product and is the first of four new product launches planned by the end of 2023. The launch of CIMERLI™ is highly anticipated in the…

Read More